| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | organic anion transmembrane transporter activity | 7.19e-05 | 293 | 16 | 4 | GO:0008514 | |
| GeneOntologyMolecularFunction | symporter activity | 2.17e-04 | 150 | 16 | 3 | GO:0015293 | |
| GeneOntologyMolecularFunction | carboxylic acid transmembrane transporter activity | 5.57e-04 | 207 | 16 | 3 | GO:0046943 | |
| GeneOntologyMolecularFunction | organic acid transmembrane transporter activity | 5.64e-04 | 208 | 16 | 3 | GO:0005342 | |
| GeneOntologyMolecularFunction | secondary active transmembrane transporter activity | 1.56e-03 | 296 | 16 | 3 | GO:0015291 | |
| GeneOntologyMolecularFunction | solute:sodium symporter activity | 1.88e-03 | 81 | 16 | 2 | GO:0015370 | |
| GeneOntologyMolecularFunction | organic cation transmembrane transporter activity | 1.97e-03 | 83 | 16 | 2 | GO:0015101 | |
| GeneOntologyMolecularFunction | amino acid transmembrane transporter activity | 3.13e-03 | 105 | 16 | 2 | GO:0015171 | |
| GeneOntologyMolecularFunction | solute:monoatomic cation symporter activity | 4.00e-03 | 119 | 16 | 2 | GO:0015294 | |
| GeneOntologyMolecularFunction | ATP hydrolysis activity | 4.84e-03 | 441 | 16 | 3 | GO:0016887 | |
| GeneOntologyMolecularFunction | active transmembrane transporter activity | 6.02e-03 | 477 | 16 | 3 | GO:0022804 | |
| GeneOntologyMolecularFunction | sodium ion transmembrane transporter activity | 8.09e-03 | 171 | 16 | 2 | GO:0015081 | |
| GeneOntologyMolecularFunction | ATP-dependent activity | 1.20e-02 | 614 | 16 | 3 | GO:0140657 | |
| GeneOntologyMolecularFunction | transmembrane transporter activity | 1.25e-02 | 1180 | 16 | 4 | GO:0022857 | |
| Domain | LRRCT | 3.36e-04 | 32 | 16 | 2 | PF01463 | |
| Domain | LRR | 6.20e-04 | 201 | 16 | 3 | PS51450 | |
| Domain | LRR_1 | 7.96e-04 | 219 | 16 | 3 | PF00560 | |
| Domain | Leu-rich_rpt | 1.47e-03 | 271 | 16 | 3 | IPR001611 | |
| Domain | - | 2.39e-03 | 321 | 16 | 3 | 3.80.10.10 | |
| Domain | L_dom-like | 2.54e-03 | 328 | 16 | 3 | IPR032675 | |
| Domain | Cys-rich_flank_reg_C | 2.64e-03 | 90 | 16 | 2 | IPR000483 | |
| Domain | LRRCT | 2.64e-03 | 90 | 16 | 2 | SM00082 | |
| Domain | LRR_8 | 9.19e-03 | 171 | 16 | 2 | PF13855 | |
| Domain | Leu-rich_rpt_typical-subtyp | 9.82e-03 | 177 | 16 | 2 | IPR003591 | |
| Domain | LRR_TYP | 9.82e-03 | 177 | 16 | 2 | SM00369 | |
| Domain | I-set | 1.12e-02 | 190 | 16 | 2 | PF07679 | |
| Domain | Ig_I-set | 1.12e-02 | 190 | 16 | 2 | IPR013098 | |
| Domain | Ig_sub2 | 1.68e-02 | 235 | 16 | 2 | IPR003598 | |
| Domain | IGc2 | 1.68e-02 | 235 | 16 | 2 | SM00408 | |
| Pathway | REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | 5.22e-04 | 238 | 10 | 3 | MM15076 | |
| Pathway | REACTOME_SLC_MEDIATED_TRANSMEMBRANE_TRANSPORT | 5.96e-04 | 249 | 10 | 3 | M5988 | |
| Pubmed | 1.98e-07 | 2 | 16 | 2 | 15203213 | ||
| Pubmed | Prognostic significance of LRIG2 and LRIG3 proteins in urothelial bladder carcinoma. | 1.98e-07 | 2 | 16 | 2 | 34839782 | |
| Pubmed | 1.98e-07 | 2 | 16 | 2 | 17393120 | ||
| Pubmed | 5.95e-07 | 3 | 16 | 2 | 18037903 | ||
| Pubmed | LRIGs: A Prognostically Significant Family with Emerging Therapeutic Competence against Cancers. | 5.95e-07 | 3 | 16 | 2 | 27628597 | |
| Pubmed | LRIG proteins regulate lipid metabolism via BMP signaling and affect the risk of type 2 diabetes. | 5.95e-07 | 3 | 16 | 2 | 33469151 | |
| Pubmed | A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. | 4.16e-06 | 7 | 16 | 2 | 20446891 | |
| Pubmed | In vivo analysis of Lrig genes reveals redundant and independent functions in the inner ear. | 5.55e-06 | 8 | 16 | 2 | 24086156 | |
| Pubmed | Lrig2 Negatively Regulates Ectodomain Shedding of Axon Guidance Receptors by ADAM Proteases. | 5.55e-06 | 8 | 16 | 2 | 26651291 | |
| Pubmed | 1.10e-04 | 34 | 16 | 2 | 18848646 | ||
| Interaction | SPSB2 interactions | 6.80e-06 | 51 | 15 | 3 | int:SPSB2 | |
| Interaction | GALP interactions | 1.08e-05 | 7 | 15 | 2 | int:GALP | |
| Interaction | SPSB4 interactions | 9.80e-05 | 124 | 15 | 3 | int:SPSB4 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr18q12 | 5.97e-04 | 104 | 16 | 2 | chr18q12 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr12q14 | 7.29e-04 | 115 | 16 | 2 | chr12q14 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr17p13 | 6.34e-03 | 346 | 16 | 2 | chr17p13 | |
| GeneFamily | Solute carriers | 7.88e-04 | 395 | 9 | 3 | 752 | |
| GeneFamily | Blood group antigens|CD molecules|I-set domain containing|Immunoglobulin like domain containing | 2.72e-03 | 161 | 9 | 2 | 593 | |
| ToppCell | systemic_lupus_erythematosus-treated-Hematopoietic-Progen-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.91e-05 | 171 | 16 | 3 | 61d622153b91702ef21b0efc7b9581e592b7ccea | |
| ToppCell | systemic_lupus_erythematosus-treated-Hematopoietic-Progen|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.91e-05 | 171 | 16 | 3 | 09b3fa120f63c411f8a0dd6bd230a9720ce83fb1 | |
| ToppCell | COVID-19-lung-Secretory|lung / Disease (COVID-19 only), tissue and cell type | 3.92e-05 | 189 | 16 | 3 | 84d48e3ed25bebb8bb8074b3a2c5e2e88cff7f25 | |
| ToppCell | PBMC_fresh-frozen-Severe-critical_progression_d03-09-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell|Severe-critical_progression_d03-09 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.05e-05 | 191 | 16 | 3 | d9a6f61fcda4f5352488f7f55cb9b57aeacc717f | |
| ToppCell | Tracheal-10x3prime_v2-Epithelial-Epi_submucosal-gland-SMG_Serous|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 4.64e-05 | 200 | 16 | 3 | 61bae10c8b12196d9cee766897971b81cb897191 | |
| Drug | butylbenzyl | 1.29e-05 | 8 | 16 | 2 | CID000007705 | |
| Drug | AC1L89QG | 1.39e-05 | 68 | 16 | 3 | CID000323970 | |
| Drug | embutramide | 3.60e-05 | 13 | 16 | 2 | CID000027453 | |
| Disease | TNF-related apoptosis-inducing ligand measurement | 6.89e-04 | 72 | 16 | 2 | EFO_0008300 | |
| Disease | mean fractional anisotropy measurement | 1.20e-03 | 95 | 16 | 2 | EFO_0008399 | |
| Disease | attempted suicide | 4.11e-03 | 178 | 16 | 2 | EFO_0004321 | |
| Disease | uterine fibroid | 5.10e-03 | 199 | 16 | 2 | EFO_0000731 | |
| Disease | nicotine dependence symptom count | 1.02e-02 | 285 | 16 | 2 | EFO_0009262 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| IFLAPVLKFIPMPVL | 826 | Q96Q91 | |
| AIPPKMFKLPQLQHL | 206 | Q6UXM1 | |
| HVNLPPLEFKPALML | 2501 | Q2LD37 | |
| LEMKFQFVRIHKPPP | 1266 | Q9C000 | |
| KILPMHFPLHLTVPK | 291 | Q9H706 | |
| LVRHYKTLPPKMPLL | 1041 | Q86UR5 | |
| PHKIKFIPSMVGPIL | 1096 | Q9H7D0 | |
| LPIFFLHLIPMLQKQ | 171 | Q9UBX8 | |
| GLPLFPLVKPHINFM | 1001 | P14735 | |
| PLLLLPLVILMPAKF | 21 | Q86YT5 | |
| LHLPKKFIATIPLVM | 306 | Q6NUT3 | |
| KLKALFLPPMTLPPH | 101 | Q99622 | |
| PLHFKVPALPLLPLM | 536 | Q8WY07 | |
| KIMEFLPVLLPRHFK | 216 | Q8NG08 | |
| PKVFLHQKPRLPKLF | 71 | Q8NA66 | |
| DIKFPPKMNHPDLLI | 416 | Q5TAX3 | |
| MIPPKIFKLPHLQFL | 206 | O94898 |